On June 3, Thermo Fisher Scientific fell 3.01% in regular trading, trading at $479.39/share, with trading volume of $315 million.

The Life Sciences Tools & Services sector broadly weakened, with peers Tempus AI down 5.13%, Illumina down 2.15%, and Danaher down 2.04%, reflecting significant sector-wide selling pressure. The latest DCF model from GuruFocus places Thermo Fisher's intrinsic value at approximately $477.60 per share, with the current stock price now approaching that level. A two-stage DCF model assumes a 10-year growth rate of 13.8%, a discount rate of 11%, and a terminal growth rate of 4%. Multiple valuation models are releasing complex signals, with some indicators suggesting overvaluation risk and weak safety margins.

Additionally, the company recently signed an agreement to divest its microbiology business for approximately $1.075 billion to European private equity firm Astorg, with the transaction expected to close in the second half of the year. This corporate restructuring uncertainty has further weighed on market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)